Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Exenatide (EXEN) is a metabolic peptide, at the fda approved stage in the published literature. Exenatide is a 39-amino acid peptide that shares approximately 53% sequence homology with human GLP-1. It was originally isolated from the saliva of the Gila monster (Heloderma suspectum), where it was identified as exendin-4 by Dr. John Eng in 1992. The peptide naturally resists degradation by the enzyme DPP-4, which rapidly breaks down native GLP-1, giving exenatide a much longer biological half-life. Exenatide was approved by the FDA in 2005 as Byetta (immediate-release, twice daily) and later in 2012 as Bydureon (extended-release, once weekly using microsphere technology). It was the first GLP-1 receptor agonist to reach market, paving the way for the entire class.
Exenatide is a 39-amino acid peptide that shares approximately 53% sequence homology with human GLP-1. It was originally isolated from the saliva of the Gila monster (Heloderma suspectum), where it was identified as exendin-4 by Dr. John Eng in 1992. The peptide naturally resists degradation by the enzyme DPP-4, which rapidly breaks down native GLP-1, giving exenatide a much longer biological half-life. Exenatide was approved by the FDA in 2005 as Byetta (immediate-release, twice daily) and later in 2012 as Bydureon (extended-release, once weekly using microsphere technology). It was the first GLP-1 receptor agonist to reach market, paving the way for the entire class.
| Research Status | FDA Approved |
|---|---|
| Half-Life | 2.4 hours (immediate-release) |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 5-10 mcg twice daily (IR) or 2 mg weekly (ER) |
| Molecular Weight | 4,186.6 Da |
| Molecular Formula | C184H282N50O60S |
Exenatide binds to and activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon, slowing gastric emptying, and promoting satiety through central nervous system mechanisms.
Exenatide is a 39-amino acid peptide that shares approximately 53% sequence homology with human GLP-1. It was originally isolated from the saliva of the Gila monster (Heloderma suspectum), where it was identified as exendin-4 by Dr. John Eng in 1992. The peptide naturally resists degradation by the enzyme DPP-4, which…
Exenatide binds to and activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon, slowing gastric emptying, and promoting satiety through central nervous system mechanisms.
Exenatide is at the following stage in the published literature: FDA Approved. All information is for research and educational purposes only.
Reported half-life: 2.4 hours (immediate-release).
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.